Summit Therapeutics (SMMT) Total Liabilities (2016 - 2025)
Historic Total Liabilities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $69.5 million.
- Summit Therapeutics' Total Liabilities rose 698.27% to $69.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.5 million, marking a year-over-year increase of 698.27%. This contributed to the annual value of $46.8 million for FY2024, which is 6262.72% down from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Total Liabilities is $69.5 million, which was up 698.27% from $64.6 million recorded in Q2 2025.
- Summit Therapeutics' Total Liabilities' 5-year high stood at $537.5 million during Q4 2022, with a 5-year trough of $22.1 million in Q3 2022.
- Its 5-year average for Total Liabilities is $98.1 million, with a median of $64.9 million in 2024.
- As far as peak fluctuations go, Summit Therapeutics' Total Liabilities soared by 168635.43% in 2022, and later crashed by 7669.7% in 2023.
- Quarter analysis of 5 years shows Summit Therapeutics' Total Liabilities stood at $30.1 million in 2021, then surged by 1686.35% to $537.5 million in 2022, then crashed by 76.7% to $125.3 million in 2023, then plummeted by 62.63% to $46.8 million in 2024, then soared by 48.39% to $69.5 million in 2025.
- Its Total Liabilities stands at $69.5 million for Q3 2025, versus $64.6 million for Q2 2025 and $39.5 million for Q1 2025.